Imaging tumor thrombus across malignancies: current concepts and the expanding role of PET/computed tomography

Tumor thrombus (TT) represents the intravascular extension of the tumor, most commonly seen in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). It is clinically significant with direct implications on staging, prognosis, and therapeutic decision-making. TT is most commonly noted in RCC and HCC, but can also occur in several other malignancies, such as adrenal cortical carcinoma, colorectal carcinoma, pancreatic neuroendocrine tumors, thyroid carcinoma, and testicular carcinoma. Differentiating TT and bland thrombus is crucial. Surgical resection offers survival benefit in select cases, whereas systemic therapies, including immunotherapy and targeted agents, are transforming the management of RCC and HCC with vascular invasion. TT is a marker of aggressive tumor biology that significantly worsens the prognosis. This review highlights current knowledge about the pathogenesis, imaging features, prognostic impact, and therapeutic approaches to TT, with emphasis on the evolving role of nuclear medicine, and provides a narrative review of peer-reviewed literature and available guidelines.

Authors

Institutions

Publication Details

Journal
Nuclear Medicine Communications
Published
2025-12-03
DOI
https://doi.org/10.1097/mnm.0000000000002090
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Imaging tumor thrombus across malignancies: current concepts and the expanding role of PET/computed tomography

Srinivas Ananth Kumar, Sanchay Jain, Harish Goyal, Dhanapathi Halanaik
Nuclear Medicine Communications
Renal cell carcinoma treatment
article

Imaging tumor thrombus across malignancies: current concepts and the expanding role of PET/computed tomography

Srinivas Ananth Kumar, Sanchay Jain, Harish Goyal, Dhanapathi Halanaik
article en

Abstract

Tumor thrombus (TT) represents the intravascular extension of the tumor, most commonly seen in renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). It is clinically significant with direct implications on staging, prognosis, and therapeutic decision-making. TT is most commonly noted in RCC and HCC, but can also occur in several other malignancies, such as adrenal cortical carcinoma, colorectal carcinoma, pancreatic neuroendocrine tumors, thyroid carcinoma, and testicular carcinoma. Differentiating TT and bland thrombus is crucial. Surgical resection offers survival benefit in select cases, whereas systemic therapies, including immunotherapy and targeted agents, are transforming the management of RCC and HCC with vascular invasion. TT is a marker of aggressive tumor biology that significantly worsens the prognosis. This review highlights current knowledge about the pathogenesis, imaging features, prognostic impact, and therapeutic approaches to TT, with emphasis on the evolving role of nuclear medicine, and provides a narrative review of peer-reviewed literature and available guidelines.

Nuclear Medicine CommunicationsVol. 47(3)
University of Iowa (US), Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
Peace, Justice and strong institutions
Openalex Percentile: Top 26%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Imaging tumor thrombus across malignancies: current concepts and the expanding role of PET/computed tomography — Srinivas Ananth Kumar, Sanchay Jain, et al. · Nuclear Medicine Communications (2025) | TGRS Research Map | TGRS